In human cancers, FOXO3a was initially categorized as a tumor suppressor because inhibition of FOXO3a transcription promoted cell transformation, tumor progression, and angiogenesis [14–17], and our previous study also showed that activation of FOXO3a was correlated with good prognosis in human gastric cancer [18]. This evidence concerns the gene FOXO3 and gastric cancer.